BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Syndax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Syndax's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06843408-3003@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06843408)
DESCRIPTION:Axatilimab\, phase 1/2\, Chronic Graft-versus-Host Disease.\nSt
 udy: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With
  Recurrent or Refractory cGVHD\nEstimated primary completion: 6 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06843408
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-3003@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06585774)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment
  for Chronic Graft-Versus-Host Disease\nEstimated primary completion: 28 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axatil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06585774
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04065399-2841@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT04065399)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rear
 rangement or NPM1 Mutation\nEstimated primary completion: 15 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04065399
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821542-3003@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06821542)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Partici
 pants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines 
 of Systemic Therapy\nEstimated primary completion: 31 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06821542
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124078-3003@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07124078)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatr
 ic Participants With Chronic Graft-Versus-Host Disease After at Least 2 Pr
 ior Lines of Systemic Therapy (AGAVE-256)\nEstimated primary completion: 3
 1 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axati
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07124078
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07211958-2841@assetmemo.bio
DTSTAMP:20261121T005900Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Revumenib: Phase 3 readout est. (NCT07211958)
DESCRIPTION:Revumenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of 
 Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Ac
 ute Myeloid Leukemia (AML) With a NPM1 Mutation\nEstimated primary complet
 ion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/revum
 enib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07211958
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
